Results 101 to 110 of about 16,400 (167)

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study. [PDF]

Blood Adv
Autore F, Tedeschi A, Benevolo G, Danesin N, Giannarelli D, Rizzi R, Cencini E, Mattiello V, Ferrarini I, Pasquale R, Del Giudice I, Ferrari A, Bullo M, Rossini B, Motta M, Marino D, Innocenti I, Stirparo L, Petrilli D, Musto P, Peri V, Zamprogna G, Hohaus S, Frustaci AM, Piazza F, Ferrero S, Laurenti L.   +26 more
europepmc   +1 more source

Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India. [PDF]

Cureus
Pradhan A, Panchal HP.
europepmc   +1 more source

APN Inhibitor Bestatin Induces MM Cell Differentiation Through the CD79B/BTK/STAT3 Pathway. [PDF]

Cells
Wang X, Fang C, Li S, Zeng H, Liu J, Duan X, Zhang X, Jiang W, Wang X.   +8 more
europepmc   +1 more source

Pharmacophore-targeted fluorescence sensing of ibrutinib <i>via</i> Michael addition-induced electron transfer on thiol-functionalized carbon dots. [PDF]

RSC Adv
Goda MN, Alqarni LS, Algethami FK, Ibrahim H, El-Wekil MM, Ali R, Almahmoud SA, Ali ABH.   +7 more
europepmc   +1 more source

Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability. [PDF]

Cancer Med
Ma Y, Dickson KA, Sarker FA, Alghalayini A, Field NR, Xie T, Skipper TS, Karafotias A, Briscas S, Yee C, Ford CE, Bowden NA, Tran N, Marsh DJ.   +13 more
europepmc   +1 more source

Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy. [PDF]

Gut Microbes
Morineau N, Tessoulin B, Guimard T, Papin M, Roquilly A, Le Gouill S, Montassier E.   +6 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis. [PDF]

Oncologist
Mushtaq A, Ahmed EN, Aljumaa R, E'mar AR, Badwan O, Ashruf O, Elshaer A, Shaik A, Baroudi M, Moudgil R, Mustafa Ali MK.   +10 more
europepmc   +1 more source

Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma. [PDF]

Cancer Res Commun
Roleder C, Zhao X, Lam V, Shen H, Dominguez EC, Chen C, Rodriguez-Rodriguez S, Wang L, Phillips T, Xia Z, Danilov AV.   +10 more
europepmc   +1 more source

Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations. [PDF]

Mol Ther Oncol
Escobar G, Maus MV.
europepmc   +1 more source